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Parthenolide exhibits anti-leukaemia activity, whilst its synthetic modification to impart improve drug-
like properties, including 1,4-conjugate addition of primary and secondary amines, have previously been
used, 1,4-addition of aniline derivatives to parthenolide has not been fully explored. A protocol for such
additions to parthenolide is outlined herein. Reaction conditions were determined using tulipane as a
model Michael acceptor. Subsequently, aniline-containing parthenolide derivatives were prepared under
the optimised conditions and single crystal X-ray diffraction structures were resolved for three of the
compounds synthesised. The synthesised derivatives, along with compounds resulting from a side re-
action, were tested for their in vitro anti-leukaemia activity using the chronic lymphocytic leukaemia
(CLL) MEC1 cell line. Computational studies with the 2RAM protein structure suggested that the activity
of the derivatives was independent of their in silico ability to dock with the Cys38 residue of NF-kB.
Crown Copyright © 2020 Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
Chronic lymphocytic leukaemia (CLL) is the most common adult
leukaemia inwestern countires [1e3]. Current treatments targeting
the disease include ibrutinib which inhibits B cell receptor (BCR)
signalling driving CLL cells out of the lymphoid tissues and the
replication centres [4] and Venetoclax which inhibits anti-
apoptotic signalling by BCL2 [5]. However, these treatments are
not curative and disease with high genome instability due to TP53-
deficiencies, eventually relapse necessitating alternative ap-
proaches [6].
Parthenolide (1) is a natural product readily extracted from
varieties of the plant feverfew (Tanacetum parthenium) [7e15] and
has been widely reported to display promising activity against
various diseases including types of cancer [16e21]. Mechanistically,
parthenolide targets leukaemia cells by depleting glutathione and. Agathanggelou), j.s.fossey@
evier Ltd. This is an open access aby alkylating Cys38 of NF-kB to inhibit DNA-binding [22,23].
However, its drug-like properties [24,25] are suboptimal for
development as an orally available drug. Great advances in
improving the bioavailability of parthenolide have been achieved
through relatively straight forward synthetic, one-step, addition to
the Michael-acceptor unit of the molecule. The most widely
employed manipulation to-date being 1,4-addition of primary and
secondary amines, such as the addition of dimethyl amine that
results in clean conversion to dimethylaminoparthenolide (DMAPT
2a, Fig. 1) [26e39]. Notably, the addition of amines leading to 2a
and analogues thereof proceeds with excellent stereoselectivity
(typically a single diastereoisomer results) without evidence of any
additional by-products arising from epoxide ring-opening. Our
team has previously utilised this approach to generate a library of
parthenolide derivatives from which compound 2b (Fig. 1), a
promising lead in addressing CLL, was identified [9]. Among re-
ported amine derivatives of parthenolide, to the best of our
knowledge [40], there are no reports of analogous N-aryl (aniline)
derivatives (3, Fig. 1). However, a crystal structure report detailing
an aniline derivative of 9-a-hydroxy parthenolide that was ob-
tained under zinc(II) chloride Lewis acid-catalysed conditions, in-
dicates feasibility of aniline introduction to related structures [41].rticle under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Table 1
Condition screening for the reaction of tulipane (4) with aniline (5a) to form model
product 6.
Entry Additive a Solvent Temp./C Time/h Yield/%
1 K2CO3 b MeOH or H2O 65e/100e 48 e
2 Et3N b MeOH 65e 48 e
3 e TEAA 20d 48 Trace
4 e TEAA 100 48 18
5 MnCl2 H2O/MeOH (1:1) 20d 48 49
6 MnCl2 c H2O/MeOH (1:1) 20d 48 47
7 MnCl2 H2O/MeOH (1:1) 65e 48 66
8 LiBF4 Neat 20d 24 79
9 LiBF4 MeOH 20d 24 35
10 LiBF4 MeOH 65e 24 85
11 Y(NO3)3$6H2O Neat 20d 16 85
12 Squaric acid H2O 20d 24 39
13 Squaric acid H2O/MeOH (1:1) 20d 24 56
14 Squaric acid H2O/MeOH (1:1) 50 20 95
15 Croconic acid H2O/MeOH (1:1) 20d 24 13
16 Croconic acid H2O/MeOH (1:1) 50 24 31
a Unless otherwise stated loaded at 10 mol%.
b 1 equiv. of additive added.
c 20 mol% catalyst loading.
d Refers to an estimated average ambient temperature without climate control.
e Refers to boiling point of the solvent mixture (heated at reflux).
Fig. 1. Structures of parthenolide (1) and previously reported derivatives thereof
DMAPT (2a) and compound 2b. Present study: N-Aryl parthenolide derivatives 3.
A.S. Quy, X. Li, L. Male et al. Tetrahedron 76 (2020) 131631Cytarabine, an N-pyrimidine anti-leukaemia drug, has been suc-
cessfully appended to PTL with a DBU catalyst [42].
Whilst the addition of primary and secondary amines to par-
thenolide generally proceeds smoothly to give compounds 2 (re-
actions between 1 and amine in a range of solvents) [9,27,28], it was
not possible, in our hands, to so readily react parthenolide with
primary or secondary aniline derivatives to form analogous prod-
ucts 3. As such the challenge to deliver and probe the anti-
leukaemic activity of the under explored aniline derivatives of
parthenolide (3) was embarked upon. This study aims to expand
the scope and breadth of compounds in this area, probe new
chemical space and test the activity of the compounds against CLL.2. Results and discussion
The 1,4-conjugate addition of primary and secondary aniline
derivative to various Michael acceptor motifs has been widely re-
ported [43e49], including related natural product derived lactones
[38,41,43,44,50] that have been shown to be amenable to Lewis or
Brønsted acid catalysed conjugate addition of anilines. In order to
extend the scope of such aniline derivative additions to partheno-
lide (1) a series of model, precedent-informed, reactions were
investigated.
Parthenolide (1) was obtained by in-house extraction from
feverfew and was deemed too valuable to be deployed in the initial
development of aniline addition methodology and as such a model
substrate was sought. Tulipane (4) was selected as a surrogate
substrate to probe conditions suitable for conjugate addition of
anilines (Table 1). Tulipane, like parthenolide, contains a five-
membered lactone ring and bares a double bond that can func-
tion as a Michael acceptor.
Tulipane (4) and aniline (5a) in the presence of one equivalent of
potassium carbonate or triethylamine failed to deliver desired
product 6 (Table 1, entry 1 (water or methanol at reflux) and entry 2
(methanol at reflux) respectively). Triethyl ammonium acetate
(TEAA) was prepared according to previously reported procedures
[51e55]. At room temperature, use of TEAA as solvent gave only a2
trace amount of product 6 (Table 1, entry 3); increasing the tem-
perature to 100 C gave 6 in 18% isolated yield (Table 1, entry 4). The
use of manganese(II) chloride as a catalyst [48] at 10 or 20 mol%
loading in a water/methanol (1:1) solvent mixture at room tem-
perature (Table 1, entries 5 and 6 respectively) resulted in the for-
mation of 6 in approximately 48% isolated yield (49 and 47%).
Increasing the temperature to 65 C (reflux, 10 mol% loading,
Table 1, entry 7) improved the yield to 66%. Under solvent-free
conditions (neat) with lithium tetrafluoroborate (10 mol%) at
room temperature for 24 h, compound 6 was formed in 79% yield
(Table 1, entry 8) [45]. Conducting the reaction inmethanol at room
temperature resulted in 35% yield, whereas heating at reflux gave a
promising 85% isolated yield (Table 1, entries 9 and 10 respectively).
Yttrium(III) nitrate hexahydrate was used at 10 mol% under
solvent-free conditions at room temperature giving compound 6 in
85% isolated yield (Table 1, entry 11) [56]. Azizi et al. showed that
squaric acid was an excellent organocatalyst for the addition of
aromatic amines (and thiols) to Michael acceptors under aqueous
conditions [46]. The formation of 6 under control of squaric acid as
catalyst (10 mol%) in water at room temperature proceeded in 39%
yield (Table 1, entry 12). When a mixture of water and methanol
(1:1) was used as solvent at room temperature the yield was 56%
which was further improved to 95% upon heating the reaction
mixture to 50 C (Table 1, entry 13 (24 h) and entry 14 (20 h)
respectively). In comparison, croconic acid as catalyst (10 mol%)
under similar conditions at room temperature or 50 C gave
product 6 in 13 and 31% isolated yield respectively (Table 1, entries
15 and 16).
Frommodel reactions of tulipane (4) and aniline (5a) detailed in
Table 1, yttrium(III) nitrate hexahydrate and squaric acid were
selected as catalysts for evaluation of their suitability to facilitate
the addition of p-toluidine (4-methylaniline, 5d) to parthenolide
(1). p-Toluidine was used in these test reactions as it allowed ready
reaction monitoring by proton NMR spectroscopy. Use of these
catalysts at 10 mol% at 50 C in a water/methanol (1:1) solvent
Table 2
Squaric acid-catalysed reaction of parthenolide (1) with aniline-containing sub-
strates to give the corresponding 1,4-conjugate addition products (3a-n).
Entry 3 R Ar Yield/%
1 3a H 72
2 3b H 77
3 3c H 75
4 3d H 51
5 3e H 35
6 3f H 9
7 3g H 54
8 3h H 26
9 3i H 28
10 3j H 24
11 3k H 18
12 3l Me 8
13 3m Me 12
14 3n Me 36
Scheme 2. Reductive amination of aniline-containing derivatives of parthenolide (3a
and 3b) with formaldehyde to give the corresponding N-methylated products 3l and
3o.
Scheme 1. Evaluation of yttrium(III) nitrate hexahydrate and squaric acid as catalysts
for the synthesis of compound 3d from p-toluidine (5d) and parthenolide (1).
Fig. 2. Single crystal XRD structure of (i) 3b and (ii) 3d. In the case of 3b (i) a molecule
of acetone has been omitted for clarity. Ellipsoid probability 30%, some hydrogen
atoms attached to nitrogen or stereogenic centres are shown, remaining hydrogen
A.S. Quy, X. Li, L. Male et al. Tetrahedron 76 (2020) 131631system gave sluggish conversion to the desired product, parthe-
nolide derivate 3d: after 48 h yttrium(III) nitrate hexahydrate gave
25% yield, squaric acid performed better with a 51% isolated yield of
product 3d (Scheme 1). Hence, squaric acid as catalyst (10 mol%) at
50 C for 48 h in a mixture of water and methanol (1:1) as solvent3
was chosen as the most suitable conditions for synthesis of a range
of aniline derivatives of parthenolide.
Under the squaric acid-catalysed aniline addition conditions
described above, a range of primary and N-methylated secondary
anilines (Table 2, entries 1 to 11 and 12 to 14 respectively) were
tested. Based on moderate to good isolated yields, no readily
discernible correlation of electronic properties of the aniline de-
rivatives used as starting materials to reaction outcomes was
observed. The best yields (>70%) were obtained for the use of an-
iline, p-hydroxy aniline and o-hydroxy aniline, resulting in products
3a-c in 72e77% isolated yield (Table 2, entries 1 to 3). Primary
aniline derivatives bearing p-methyl or p-methoxy substituents
gave products 3d and 3g in 51 and 54% isolated yield respectively
(Table 2, entries, 4 and 7 respectively). The remaining six primary
anilines tested all gave rise to the corresponding desired products,
albeit in yields below 40%. Three N-methylated secondary anilines
were tested as substrates for the same squaric acid-catalysed pro-
tocol (Table 2, entries 12 to 14). Unfortunately, the N-methylated
congener of 3a (3l) was formed in only 8% isolated yield. p-Fluoro-
and p-methoxy analogues did not fare much better giving rise to
3m and 3n in 12 and 36% isolated yield respectively. Since tertiary
amine derivatives of parthenolide have shown superior pharma-
ceutical properties (e.g. 2a and 2b, Fig. 1) it was reasoned that
alternative access to tertiary aniline products should be probed.
Since secondary aniline-containing derivatives of parthenolideatoms were omitted for clarity (Ortep III for Windows and PovRay) [57].
Table 3
Cytotoxic activity against the MEC1 CLL cell line and in silico docking score to Cys38
NF-kB.
Entry Compound Docking Score(a) LC50 (mM)(b)
1 1 5.3 4.6 ± 0.9
2 2a 4.5 3.4 ± 1.0
3 2b 6.4 5.3 ± 0.5
4 3a 5.2 >20.0
5 3b 5.2 12.5 ± 1.2
6 3c 5.3 11.7 ± 1.3
7 3d 5.2 >100.0
8 3e 5.2 >100.0
Scheme 3. Squaric acid-mediated reaction of parthenolide (1) with methanol to give 7,
and its subsequent reaction with dimethylamine to give 8.
Fig. 4. Concentration versus activity plots showing the anti-leukaemic activity of N-
aryl derivatives (3) derivatives versus parthenolide (1) and amine derivatives 2a and
2b.
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synthetic access, Table 2) they were selected as substrates upon
which to probe the suitability of reductive amination as a strategy
to deliver N-alkylated tertiary aniline derivatives (Scheme 2). Upon
reaction of 3a or 3b with formaldehyde with an excess of sodium
acetoxy borohydride in 1,2-dichloromethane the corresponding
desired products 3l and 3o were furnished both in 61% isolated
yield. Whilst the yields over the two-steps required to generate
them are in the region of 45% this represents a significant
improvement over the one-step reaction of N-methylated anilines
with parthenolide (compare the one-step yield of 3l of 8% to the
two-step reductive amination route giving 3l in 44% yield overall).
Reductive amination is therefore confirmed to be a compatible
strategy for N-alkylation of secondary aniline-containing de-
rivatives of parthenolide.
The structures and relative stereochemistries of 3b and 3dwere
confirmed by single crystal X-ray diffraction structure determina-
tion of the isolated major products (Fig. 2). Thus, the stereo-
selectivity of aniline additionwas determined to be consistent with
that previously reported for the more facile addition of primary and
secondary amines, i.e. generation of (R) stereogenic carbon centres,
alpha to the carbonyl in these cases. The absolute stereochemistry
of the remaining highly diastereoselective (single isomer detected)
squaric acid-catalysed aniline-derivative addition products of
Table 2 were assigned by analogy.
Exposure of parthenolide 1 to acidic conditions in methanol as
solvent have been reported to lead to epoxide ring-opening re-
actions. Although not detected in the reactions of Table 2 uniden-
tified side-products were observed in very low quantities in earlier
reactions (Scheme 1). In order to ascertain the nature of the un-
identified side-products and to probe whether the squaric acid
catalyst could lead to loss of starting material, a blank reaction inFig. 3. Single crystal XRD structure of one independent molecule of 7. The asymmetric
unit contains two molecules of 7 and one of water. Ellipsoid probability 30%, some
hydrogen atoms omitted for clarity (Ortep III for Windows and PovRay) [54].
4
the absence of aniline (or derivative thereof) was performed where
parthenolide was treated with squaric acid (10 mol%), Scheme 3.
After 72 h, and no further development of product(s) as judged
by TLC analysis, the reaction of parthenolide 1 in methanol with
squaric acid revealed the formation of O-methylated transannular
epoxide ring-open product 7 in 40% isolated yield. Compound 7
was not altogether an unexpected result; it has been previously
reported to result from the reaction of parthenolide with methanol
in acidic conditions and aspects of its biological activity have been
probed [58e60]. Furthermore, with an authentic sample of 7 in-
hand it was possible to confirm the small amounts of side prod-
ucts formed in earlier experiments were indeed likely to be com-
pound 7. Compound 7was analysed by single crystal XRD structure
determination which confirmed the identity and relative stereo-
chemistry to be that depicted (Fig. 3). Since compound 7 retains the
Michael acceptor motif of the parent compound and attempt to
derivatise it with the well-understood dimethyl amine group, in
order to furnish 8, an analogue of 2a, was made (Scheme 3).
Treatment of 7 with dimethylamine and potassium carbonate in
ethanol for 16 h resulted in the formation of the expected product 89 3f 5.1 >100.0
10 3g 5.1 >100.0
11 3h 5.1 >100.0
12 3i 5.3 >100.0
13 3j 5.3 >100.0
14 3k 5.4 >100.0
15 3l 5 >100.0
16 3m 5 >100.0
17 3n 4.9 76.2 ± 0.3
18 3o 5.1 12.9 ± 1.9
19 7 5.6 14.8
a Best pose calculated from docking each molecule with the p65 subunit of NF-kB
with structure code 2RAM centred on Cys38.
b LC50 values (CalcuSyn) from dose-response curves generated using low
(0e20 mM) or high (0e100 mM) concentrations.
A.S. Quy, X. Li, L. Male et al. Tetrahedron 76 (2020) 131631in 89% isolated yield. In order to establish the potential applicability
of this structural class as anti-leukaemic compounds 7 and 8 were
retained and subjected to in vitro cell-based assays below (see
Fig. 4).
Derivatisation of parthenolide 1 has beenwidely used to alter its
biochemical and pharmacokinetic properties. Inspired by the work
of Neelakantan et al. in identifying compound 2a as a promising NF-
kB inhibitor [28], the co-authors of this report had previously
identified compound 2b as a potential anti-CLL therapy [8,9], which
showed improved drug metabolism and pharmacokinetics (DMPK)
properties. To the best of our knowledge the anti-leukaemic activity
of aniline-derivatisation on parthenolide has not previously been
addressed.
To investigate the anti-leukaemic activity of aniline derivatise
3a-o, the MEC1 chronic lymphocytic leukaemia (CLL) cell line was
used. MEC1 is p53-deficient and represents a treatment-refractory
model of CLL [61]. The alamarBlue® assay was employed to mea-
sure their in vitro anti-leukaemic and LC50 values were determined
using CalcuSyn (Biosoft) software, Table 3. The LC50 values of par-
thenolide (1), 2a and 2b are consistent with previously published
reports (Table 3, 4.6, 3.4 and 5.3 mM, entries 1, 2 and 3 respectively)
[9]. The most active aniline derivatives were phenol-containing 3b,
3c and 3o LC50 values of 12.5, 11.7 and 12.9 mM respectively (Table 3,
entries 5, 6 and 18). Whilst a control experiment confirmed p- and
o-aminophenol were in themselves inactive against CLL, the sig-
nificance of the phenol functionality to the observed activity in
these derivatives remains to be elucidated. Compounds 3a, 3d-m
and 3n did not show appreciable activity (with LC50 determined as
>20, >100 and 76.2 mM, Table 3, entry 4, entries 7e16 and 17
respectively). The non-aniline-bearing analogues of 1 and 2a,
compounds 7 and 8 showed reduced cytotoxic activity (Table 3,
entries 1 and 2 versus entries 19 and 20, LC50 values of 4.6 and
3.4 mM versus 14.8 and 14.0 mM respectively).
One biological mechanism by which the active compounds may
act is through inhibition of the binding between DNA and the p65
domain of NF-kB [22,23] through binding with the Cys38 residue
on this protein [59,60]. A series of docking scores were determined
using the software Chimera and the structure code 2RAM from the
Protein Data Bank. The 3D representations of the parthenolide
derivatives were first minimised using MM2 minimisation calcu-
lations. Using default settings of Autodock Vina code, and a binding
site centred on the Cys38 residue with an 18 Å box of enclosure, all
the molecules were analysed with the lowest scoring pose con-
trasted [62]. The results obtained do not show any significant
variance in docking score and as such the aniline derivatisation of
parthenolide is unlikely to affect its ability to alkylate NF-kB.
Additionally, the retro-Michael addition reaction that occurs in
the cell invokes the release of PTL, being the active metabolite.
Therefore, docking of the aniline does not directly confirm an in-
hibition of NF-kB mechanism.
3. Conclusion
Successful protocols for the synthesis of aniline-derivatives of
parthenolide were developed. The use of squaric acid as an orga-
nocatalyst facilitated 1,4-conjugate addition of aniline and aniline
derivatives to parthenolide and will permit exploration of hitherto
inaccessible chemical space. Aminophenol-containing aniline de-
rivatives of parthenolide 3b, 3c and 3o were the most potent anti-
leukaemic compounds among the aniline derivatives tested. Par-
thenolide has demonstrated potential in a addressing a range of
cancer types [30,63e66], attempts to improve its drug-like prop-
erties have focused mostly on alkyl amine-derivatisation
[9,27,28,31]. Elucidation of methodology herein, that expands the
synthetic scope to aniline-derivatives, enables the exploration of5
hitherto uncharted chemical space in the study of parthenolide, its




All commercially available solvents, catalysts and reagents were
purchased and used from suppliers without any further purifica-
tion. Proton NMR spectra were recorded at 400 MHz on a Bruker
AVIII400 NMR spectrometer. Carbon NMR spectra are proton
decoupled and were recorded at 101 MHz on a Bruker AVIII400
NMR spectrometer at room temperature. Fluorine NMR spectra are
proton decoupled and were recorded at 377 MHz on a Bruker
AVIII400NMR spectrometer at room temperature. Chemical shifts
(d) were reported in ppm relative to TMS (d 0.00) for 1H NMR and to
chloroform (d 77.16) for 13C NMR spectroscopy; coupling constants
(J) are expressed in Hertz (Hz). The following abbreviations are
used for multiplicities: s ¼ singlet, d ¼ doublet, t ¼ triplet,
q ¼ quartet, quint ¼ quintet, m ¼ multiplet, pent ¼ pentet,
hex ¼ hextet, and br ¼ broad. Mass spectra were recorded on an
electrospray MS Waters LCT Time of Flight Mass Spectrometer and
with EI (GC/MS) Waters GCT Premier Time of Flight Mass Spec-
trometer. Infrared Spectra Varian 660-IR FT-IR spectrometer at
room temperature using an ATR attachment. Melting points were
measured using a StuartTM digital melting point apparatus
(SMP10) and reported as a range. Specific optical rotations were
recorded on an Optical PolAAr 2001 automatic polarimeter at room
temperature. The X-ray crystal structures were determined using
an Agilent SuperNova X-ray diffractometer with an Atlas detector
(wavelength 1.5418 Å). Column chromatography was carried out
using standard flash column chromatography and a Combiflash Rf
200i (stationary phase silica), chromatograms were recorded by
evaporative light scattering detector (ELSD) and absorbance at two
wavelengths (254 nm and 280 nm). Reactions were monitored by
thin layer chromatography (TLC) on Merck silica gel 60 F254 plates.
TLC plates were visualised by either UV light with 254 nm/365 nm,
a methanolic solution of ninhydrin or with potassium
permanganate.
4.1.2. Biological assays
Tissue culture, MEC1 cells were obtained from the American
Type Culture Collection (Manassas, VA 20110 USA) and were
cultured in RPMI 1640 medium (Sigma-Aldrich, Irvine, UK) with
10% fetal bovine serum (Sigma-Aldrich). The alamarBlue® cyto-
toxicity assay was conducted by seeding MEC1 cells in triplicate at
density of 25000 cells/well in a 96 well plate, final volume of 200 mL
[67]. Following treatment with test compound, viability was
determined by measuring the reduction of resazurin. Resazurin
solutionwas added to eachwell at a final concentration of 50 mg/mL
and incubated for 3 h at 37 C with 5% CO2. Reduction of resazurin
was determined by measuring absorbance at 590 nm using a
PheraSTAR FS plate reader (BMG Labtech). Cell viability was
calculated as a fraction of the untreated cells after subtracting
background fluorescence of resazurin in media only. Data is pre-
sented as the mean of five independent experiments and signifi-
cance was determined by Student’s t-test.
4.1.3. General procedure A: synthesis of aryl aminoparthenolide
derivatives
To a 1:1 water-methanol (0.2 M) solution of a,b-unsaturated
ester (1 equiv.), the corresponding aniline (1.2 equiv.) and squaric
acid (10 mol%.) were added. The resulting solution was stirred at
50 C for 48 h. The solution was cooled to room temperature and
A.S. Quy, X. Li, L. Male et al. Tetrahedron 76 (2020) 131631the solvent was removed in vacuo. The residual was extracted with
dichloromethane (3  25 mL), the combined organic layers were
washed with brine and then dried over anhydrous magnesium
sulphate, filtered, and solvent removed in vacuo. The product was
isolated by flash chromatography over silica gel.
4.1.4. General procedure B: synthesis of tertiary aniline
parthenolide derivatives from secondary aniline parthenolide
derivatives
To a solution of aniline secondary derivative (1 equiv.) in 1,2-
dichloroethene (10 mL), formaldehyde (2 equiv.) and sodium tri-
acetoxyborohydride (3 equiv.) were added. The reaction mixture
was stirred under nitrogen protection at room temperature for 48 h
and quenched with saturated aqueous sodium bicarbonate. The
solvent was removed in vacuo and the residual was extracted with
ethyl acetate. The combined organic solution was dried over
anhydrousmagnesium sulphate, filtered and concentrated in vacuo.
Further purification was carried out by flash chromatography over
silica gel.
4.2. Chemical synthesis
4.2.1. Synthesis of 3a (3R,3aS,9aR,10aR,10bS,E)-6,9a-Dimethyl-3-
((phenylamino)methyl)-3a,4,5,8,9,9a,10a,10b-octahydrooxireno
[20,3’:9,10]cyclodeca[1,2-b]furan-2(3H)-one
Following general procedure A, a mixture of parthenolide
(150 mg, 0.605 mmol), aniline (75 mg, 0.80 mmol) and squaric acid
(7 mg, 0.06 mmol), was stirred at 50 C in 1:1 water-methanol
(20 mL) for 48 h. The title compound was obtained as a pale-
yellow oil in 72% yield (148 mg, 0.434 mmol). Rf ¼ 0.49 (hexane/
ethyl acetate, 50%:50%); 1H NMR (400MHz, CDCl3): d 7.21e7.17 (2H,
m, ArH), 6.74 (1H, t, J 7.3, ArH), 6.65 (2H, dd, J 8.6 & 0.9, ArH), 5.12
(1H, dd, J 12.0 & 2.2, CH), 4.44 (1H, br s, NH), 3.84 (1H, t, J 9.0, CH),
3.58 (1H, dd, J 13.8 & 3.9, CH2), 3.39 (1H, dd, J 13.8 & 6.7, CH2), 2.68
(1H, d, J 9.1, CH, epoxide moiety), 2.60e2.52 (1H, m, CH), 2.43e2.26
(2H, m), 2.18e2.08 (3H, m), 2.07e1.93 (2H, m), 1.76e1.66 (1H, m,
CH2), 1.68 (3H, s, Me), 1.27 (3H, s, Me), 1.20 (1H, td, J 15.9& 3.0 CH2);
13C NMR (101 MHz, CDCl3): d 176.5 (C¼O), 147.8 (Cq), 134.3 (Cq),
129.4 (CH), 125.3 (CH), 118.2 (CH), 113.3 (CH), 82.6 (CH), 66.2 (CH,
epoxide moiety), 61.6 (Cq), 47.5 (CH), 46.8 (CH), 42.0 (CH2), 41.0
(CH2), 36.6 (CH2), 30.1 (CH2), 24.1 (CH2), 17.2 (CH3), 16.9 (CH3); IR
(neat, cm1) 1761 (C¼O); HRMS (ESþ) m/z: [MþNa]þ calc. for
C21H27NO3Naþ: 364.1889, found: 364.1887; [a]D20 ¼ 0.26 (c 10.0,
CHCl3).




Following general procedure A, a mixture of parthenolide
(200 mg, 0.806 mmol), 4-aminophenol (119 mg, 1.06 mmol) and
squaric acid (9 mg, 0.08 mmol), was stirred at 50 C in 1:1 water-
methanol (20 mL) for 48 h. The title compound was obtained as a
colourless solid in 77% yield (223 mg, 0.625 mmol). Rf ¼ 0.46
(hexane/ethyl acetate, 50%:50%); 1H NMR (400 MHz, CDCl3): d 6.71
(2H, d, J 8.7, ArH), 6.56 (2H, d, J 8.7, ArH), 5.15 (1H, dd, J 11.8 & 2.0,
CH), 3.83 (1H, t, J 9.0, CH), 3.48 (1H, dd, J 13.6 & 3.8, CH2), 3.29 (1H,
dd, J 13.5 & 7.2, CH2), 2.70 (1H, d, J 9.0, CH, epoxide moiety),
2.59e2.50 (1H, m, CH), 2.44e2.24 (2H, m), 2.19e2.07 (3H, m),
2.04e1.88 (2H, m), 1.74e1.61 (1H, m, CH2), 1.67 (3H, s, Me), 1.27 (3H,
s, Me), 1.18 (1H, td, J 12.8 & 5.8, CH2); 13C NMR (101 MHz, CDCl3):
d 176.9 (C¼O), 148.9 (Cq), 141.2 (Cq), 134.4 (Cq), 125.2 (CH), 116.4
(CH), 115.5 (CH), 82.6 (CH), 66.3 (CH, epoxide), 61.9 (Cq), 47.0 (CH),
46.9 (CH), 43.6 (CH2), 41.0 (CH2), 36.5 (CH2), 30.1 (CH2), 24.1 (CH2),
17.2 (CH3), 16.9 (CH3); IR (neat, cm1) 3345 (OH), 1758 (C¼O);6
HRMS (ESþ) m/z: [MþNa]þ calc. for C21H27NO4Naþ: 380.1838,
found: 380.1831; mp: 85e87 C; [a]D20 ¼ 7.42 (c 7.0, CHCl3).




Following general procedure A, a mixture of parthenolide
(100 mg, 0.403 mmol), 2-aminophenol (88 mg, 0.40 mmol) and
squaric acid (5 mg, 0.04 mmol), was stirred at 50 C in 1:1 water-
methanol (20 mL) for 48 h. The title compound was obtained as a
colourless solid in 75% yield (107 mg, 0.300 mmol). Rf ¼ 0.40
(hexane/ethyl acetate, 50%:50%); 1H NMR (400 MHz, CDCl3): d 6.88
(2H, m, ArH), 6.75 (2H, m, ArH), 5.10 (1H, dd, J 11.8 & 1.8, CH), 3.85
(1H, t, J 9.0, CH), 3.56 (1H, dd, J 13.7&4.0, CH2), 3.44 (1H, dd, J 13.7&
6.2, CH2), 2.71 (1H, d, J 8.9, CH, epoxide moiety), 2.65e2.56 (1H, m,
CH), 2.43e2.22 (2H, m), 2.20e2.08 (3H, m), 2.05e1.90 (2H, m),
1.72e1.64 (1H, m, CH2), 1.68 (3H, s, Me), 1.28 (3H, s, Me), 1.20 (1H,
td, J 12.8 & 5.9, CH2); 13C NMR (101 MHz, CDCl3): d 176.7 (C¼O),
144.8 (Cq), 136.4 (Cq), 134.4 (Cq), 125.2 (CH), 121.3 (CH), 119.1 (CH),
115.0 (CH), 113.2 (CH), 82.6 (CH), 66.3 (CH, epoxide moiety), 61.8
(Cq), 47.7 (CH), 46.9 (CH), 42.7 (CH2), 41.0 (CH2), 36.5 (CH2), 30.1
(CH2), 24.1 (CH2), 17.2 (CH3), 16.9 (CH3); IR (neat, cm1) 3386 (OH),
1764 (C¼O); HRMS (ESþ) m/z: [MþH]þ calc. for C21H28NO4þ:
358.2018, found: 358.2016; mp: 195e198 C; [a]D20 ¼ 1.08 (c 2.3,
CHCl3).
4.2.4. Synthesis of 3d (3R,3aS,9aR,10aR,10bS,E)-6,9a-dimethyl-3-
((p-tolylamino)methyl)-3a,4,5,8,9,9a,10a,10b-octahydrooxireno
[20,3’:9,10]cyclodeca[1,2-b]furan-2(3H)-one
Following general procedure A, a mixture of parthenolide
(100 mg, 0.403 mmol), p-toluidine (52 mg, 0.48 mmol) and squaric
acid (5 mg, 0.04 mmol) was stirred at 50 C in 1:1 water-methanol
(2 mL) for 48 h. The title compoundwas obtained as awhite solid in
51% yield (73 mg). Rf ¼ 0.65 (hexane/ethyl acetate, 50%:50%); 1H
NMR (400 MHz, CDCl3) d 7.01 (2H, d, J 8.2), 6.58 (2H, d, J 8.4), 5.13
(1H, d, J 8.9), 4.28 (1H, s), 3.84 (1H, t, J 9.1), 3.56 (1H, d, J 13.8), 3.36
(1H, dd, J 13.7 & 6.8), 2.69 (1H, d, J 8.9), 2.60e2.51 (1H, m),
2.43e2.27 (2H, m), 2.24 (3H, s), 2.20e1.93 (5H, m), 1.76e1.60 (1H,
m), 1.69 (3H, s), 1.28 (3H, s), 1.19 (1H, td, J 13.4 & 5.8); 13C NMR
(101 MHz, CDCl3) d 176.5, 145.5, 134.3, 129.9, 127.6, 125.3, 113.6,
82.5, 66.2, 61.6, 47.4, 46.8, 42.5, 41.1, 36.6, 30.1, 24.1, 20.4, 17.2, 16.9;
IR (neat, cm1) 3363 (NH), 1747 (C¼O); HRMS (TOF MS ESþ) m/z:
[MþH]þ calc. for C22H30NO3þ 356.2224, found 356.2226; mp
200e203 C; [a]D22 ¼ 12.81 (c 2.0, CH2Cl2).
4.2.5. Synthesis of 3e (3R,3aS,9aR,10aR,10bS,E)-3-(((4-
Fluorophenyl)amino)methyl)-6,9a-dimethyl-3a,4,5,8,9,9a,10a,10b-
octahydrooxireno[20,3’:9,10]cyclodeca[1,2-b]furan-2(3H)-one
Following general procedure A, a mixture of parthenolide
(100 mg, 0.403 mmol), 4-fluoroaniline (54 mg, 0.48 mmol) and
squaric acid (5 mg, 0.04 mmol) was stirred at 50 C in 1:1 water-
methanol (2 mL) for 48 h. The title compound was obtained as a
white solid in 35% yield (51 mg). Rf ¼ 0.57 (hexane/ethyl acetate,
50%:50%); 1H NMR (400 MHz, CDCl3) d 6.97e6.86 (2H, m),
6.66e6.56 (2H, m), 5.15 (1H, d, J 12.3), 4.37 (1H, s), 3.87 (1H, t, J 9.0),
3.54 (1H, dd, J 13.5 & 3.8), 3.34 (1H, dd, J 13.5 & 7.1), 2.70 (1H, d, J
8.9), 2.56 (1H, ddd, J 12.4, 7.1 & 3.8), 2.47e2.28 (2H, m), 2.22e1.91
(5H, m), 1.81e1.67 (1H, m), 1.70 (3H, s), 1.29 (3H, s), 1.27e1.14 (1H,
m); 13C NMR (101 MHz, CDCl3) d 176.4, 157.5, 144.0, 134.2, 125.4,
116.0, 115.8, 114.5, 114.4, 82.6, 66.2, 61.6, 47.3, 46.9, 43.0, 41.1, 36.5,
30.1, 24.1, 17.2, 16.9; 19F NMR (377 MHz, CDCl3) d 126.83; IR (neat,
cm1) 3371 (NH), 1748 (C¼O); HRMS (TOF MS ESþ) m/z: [MþH]þ
calc. for C21H27NO3þ 360.1974, found 360.1975; mp 121e124 C;
[a]D22 ¼ 19.39 (c 0.5, CH2Cl2).
A.S. Quy, X. Li, L. Male et al. Tetrahedron 76 (2020) 1316314.2.6. Synthesis of 3f (3R,3aS,9aR,10aR,10bS,E)-3-(((4-
Bromophenyl)amino)methyl)-6,9a-dimethyl-3a,4,5,8,9,9a,10a,10b-
octahydrooxireno[20,3’:9,10]cyclodeca[1,2-b]furan-2(3H)-one
Following general procedure A, a mixture of parthenolide
(100 mg, 0.403 mmol), 4-bromoaniline (83 mg, 0.48 mmol) and
squaric acid (5 mg, 0.04 mmol) was stirred at 50 C in 1:1 water-
methanol (2 mL) for 48 h. The title compound was obtained as a
white solid in 9% yield (15 mg). Rf ¼ 0.57 (hexane/ethyl acetate,
50%:50%); 1H NMR (400 MHz, CDCl3) d 7.31e7.23 (2H, m),
6.58e6.49 (2H, m), 5.14 (1H, d, J 12.1), 4.48 (1H, t, J 6.8), 3.91e3.82
(1H, m), 3.59e3.52 (1H, m) 3.39e3.31 (1H, m), 2.69 (1H, d, J 8.9),
2.59e2.52 (1H, m), 2.45e2.28 (2H, m), 2.21e1.93 (5H, m), 1.79e1.70
(1H, m), 1.70 (3H, s), 1.29 (3H, s), 1.30e1.16 (1H, m); 13C NMR
(101 MHz, CDCl3) d 176.3, 146.7, 134.2, 132.2, 125.5, 114.9, 109.9,
82.6, 66.2, 61.6, 60.4, 47.4, 46.9, 42.1, 41.1, 36.5, 30.1, 24.1, 17.2, 16.9,
14.2; IR (neat, cm1) 3380 (NH), 1760 (C¼O); HRMS (TOF MS
ASAPþ) m/z: [MþH]þ calcd. for C21H27BrNO3þ 420.1174 found
420.1179; mp 182e184 C; [a]D22 ¼ 9.70 (c 0.5, CH2Cl2).




Following general procedure A, a mixture of parthenolide
(100 mg, 0.403 mmol), 4-methoxyaniline (60 mg, 0.48 mmol) and
squaric acid (5 mg, 0.04 mmol) was stirred at 50 C in 1:1 water-
methanol (2 mL) for 48 h. The title compound was obtained as a
white solid in 54% yield (81 mg). Rf ¼ 0.50 (hexane/ethyl acetate,
50%:50%); 1H NMR (400 MHz, CDCl3) d 6.84e6.75 (2H, m),
6.68e6.60 (2H, m), 5.13 (1H, d, J 12.2), 4.21 (1H, s), 3.85 (1H, t, J 9.0),
3.75 (3H, s), 3.53 (1H, dd, J 13.5 & 3.8), 3.33 (1H, dd, J 13.5 & 7.0),
2.70 (1H, d, J 8.9), 2.56 (1H, ddd, J 12.3, 6.9 & 3.8), 2.45e2.26 (2H,
m), 2.21e1.91 (5H, m), 1.78e1.65 (1H, m), 1.69 (3H, s), 1.28 (3H, s),
1.20 (1H, td, J 13.0 & 5.9); 13C NMR (101 MHz, CDCl3) d 176.6, 152.7,
141.8, 134.3, 125.3, 115.0, 82.6, 66.2, 61.6, 55.8, 47.2, 46.9, 43.4, 41.1,
36.6, 30.0, 24.1, 17.2, 16.9; IR (neat, cm1) 3365 (NH), 1747 (C¼O);
HRMS (TOF MS ESþ) m/z: [MþH]þ calcd. for C22H30NO4þ 372.2175,
found 372.2174; mp 145e147 C; [a]D22 ¼ 16.62 (c 1.0, CH2Cl2).




Following general procedure A, a mixture of parthenolide
(100 mg, 0.403 mmol), 3,5-dimethoxyaniline (74 mg, 0.48 mmol)
and squaric acid (5 mg, 0.04 mmol) was stirred at 50 C in 1:1
water-methanol (2 mL) for 48 h. The title compound was obtained
as a white solid in 26% yield (42 mg). Rf ¼ 0.50 (hexane/ethyl ac-
etate, 50%:50%); 1H NMR (400 MHz, CDCl3) d 5.91 (1H, t, J 2.1), 5.83
(2H, d, J 2.1), 5.13 (1H, dd, J 11.9& 2.3), 4.47 (1H, s), 3.86 (1H, t, J 9.0),
3.75 (6H, s), 3.56 (1H, dd, J 14.5 & 3.3), 3.36 (1H, dd, J 13.8 & 6.8),
2.69 (1H, d, J 8.9), 2.57 (1H, ddd, J 12.3, 6.8 & 3.7), 2.46e2.27 (2H,
m), 2.21e1.94 (5H, m), 1.80e1.70 (1H, m), 1.69 (3H, s), 1.29 (3H, s),
1.20 (1H, td, J 13.4 & 6.3); 13C NMR (101 MHz, CDCl3) d 176.4, 161.9,
149.7, 134.3, 125.4, 92.1, 90.4, 82.6, 66.2, 61.6, 55.2, 47.5, 46.8, 41.8,
41.0, 36.6, 30.1, 24.1, 17.2, 16.9; IR (neat, cm1) 3389 (NH), 1761
(C¼O); HRMS (TOF MS ESþ) m/z: [MþH]þ calcd. for C23H32NO5þ
402.2280, found 402.2285; mp 110e112 C; [a]D22 ¼ 5.02 (c 2.0,
CH2Cl2).




Following general procedure A, a mixture of parthenolide7
(100mg, 0.403mmol), 3,5-dimethylaniline (54mg, 0.48 mmol) and
squaric acid (5 mg, 0.04 mmol) was stirred at 50 C in 1:1 water-
methanol (2 mL) for 48 h. The title compound was obtained as a
white solid in 28% yield (42 mg). Rf ¼ 0.62 (hexane/ethyl acetate,
50%:50%); 1H NMR (400MHz, CDCl3) d 6.41 (1H, s), 6.28 (2H, s), 5.12
(1H, dd, J 12.1 & 2.3), 4.27 (1H, s), 3.84 (1H, t, J 9.0), 3.58 (1H, dd, J
13.8 & 3.8), 3.39 (1H, dd, J 13.8 & 6.3), 2.68 (1H, d, J 8.9), 2.55 (1H,
ddd, J 12.3, 6.3 & 3.8), 2.45e2.27 (2H, m), 2.24 (6H, s), 2.20e1.95
(5H, m), 1.79e1.66 (1H, m), 1.70 (3H, s), 1.29 (3H, s), 1.19 (1H, td, J
13.0 & 6.0); 13C NMR (101 MHz, CDCl3) d 176.4, 147.9, 139.1, 134.3,
125.4, 120.2, 111.3, 82.5, 66.2, 61.6, 47.8, 46.7, 42.0, 41.0, 36.6, 30.1,
24.1, 21.5, 17.2, 16.9; IR (neat, cm1) 3382 (NH), 1755 (C¼O); HRMS
(TOF MS ESþ) m/z: [MþH]þ calcd. for C23H32NO3þ 370.2383, found
370.2382; mp 196e197 C; [a]D22 ¼ 11.08 (c 0.5, CH2Cl2).




Following general procedure A, a mixture of parthenolide
(80 mg, 0.32 mmol), 3-methoxyaniline (48 mg, 0.38 mmol) and
squaric acid (4 mg, 0.03 mmol) was stirred at 50 C in 1:1 water-
methanol (2 mL) for 48 h. The title compound was obtained as a
white solid in 24% yield (28 mg). Rf ¼ 0.52 (hexane/ethyl acetate,
50%:50%); 1H NMR (400 MHz, CDCl3) d 7.10 (1H, t, J 8.1), 6.31 (1H,
dd, J 8.2 & 2.4), 6.26 (1H, dd, J 8.0 & 2.2), 6.20 (1H, t, J 2.3), 5.13 (1H,
d, J 12.2 & 2.4), 4.43 (1H, s), 3.85 (1H, t, J 9.0), 3.77 (3H, s), 3.58 (1H,
dd, J 14.1 & 3.6), 3.39 (1H, dd, J 13.8 & 6.7), 2.69 (1H, d, J 8.9), 2.56
(1H, ddd, J 12.3, 6.7 & 3.8), 2.46e2.25 (2H, m), 2.20e1.94 (5H, m),
1.79e1.66 (1H, m), 1.69 (3H, s), 1.29 (3H, s), 1.27e1.14 (1H, m); 13C
NMR (101 MHz, CDCl3) d 176.4, 161.0, 149.2, 134.3, 130.2, 125.4,
106.3, 103.4, 99.4, 82.6, 66.2, 61.6, 55.2, 47.6, 46.8, 41.9, 41.0, 36.6,
30.1, 24.1, 17.2, 16.9; IR (neat, cm1) 2930 (NH), 1762 (C¼O); HRMS
(TOF MS ESþ) m/z: [MþH]þ calcd. for C22H30NO4þ 372.2175, found
372.2177; mp 154e156 C; [a]D22 ¼ 17.31 (c 1.0, CH2Cl2).
4.2.11. Synthesis of 3k (3R,3aS,9aR,10aR,10bS,E)-6,9a-dimethyl-3-
((m-tolylamino)methyl)-3a,4,5,8,9,9a,10a,10b-octahydrooxireno
[20,3’:9,10]cyclodeca[1,2-b]furan-2(3H)-one
Following general procedure A, a mixture of parthenolide
(80 mg, 0.32 mmol), m-toluidine (42 mg, 0.38 mmol) and squaric
acid (4 mg, 0.03 mmol) was stirred at 50 C in 1:1 water-methanol
(2 mL) for 48 h. The title compoundwas obtained as awhite solid in
18% yield (20 mg). Rf ¼ 0.64 (hexane/ethyl acetate, 50%:50%); 1H
NMR (400 MHz, CDCl3) d 7.08 (1H, t, J 7.5), 6.57 (1H, d, J 7.2),
6.50e6.43 (2H, m), 5.12 (1H, dd, J 12.2 & 3.8), 4.35 (1H, s), 3.85 (1H,
t, J 9.0), 3.58 (1H, dd, J 13.8 & 3.9), 3.40 (1H, dd, J 13.8 & 6.6), 2.68
(1H, d, J 8.9), 2.56 (1H, ddd, J 12.2, 6.5 & 3.8), 2.45e2.30 (2H, m),
2.28 (3H, s), 2.20e1.95 (5H, m), 1.79e1.66 (1H, m), 1.69 (3H, s), 1.29
(3H, s), 1.19 (1H, td, J 13.0 & 5.9); 13C NMR (101 MHz, CDCl3) d 176.4,
147.8, 139.3, 134.3, 129.3, 125.4, 119.2, 114.2, 110.4, 82.6, 66.2, 61.6,
47.6, 46.8, 42.0, 41.0, 36.6, 30.1, 24.1, 21.6, 17.2, 16.9; IR (neat, cm1)
3385 (NH), 1761 (C¼O); HRMS (TOF MS ESþ) m/z: [MþH]þ calc. for
C22H30NO3þ 356.2224, found 356.2230; mp 154e156 C;
[a]D22 ¼ 7.62 (c 0.5, CH2Cl2).
4.2.12. Synthesis of 3l (3R,3aS,9aR,10aR,10bS,E)-6,9a-dimethyl-3-
((methyl(phenyl)amino)methyl)-3a,4,5,8,9,9a,10a,10b-
octahydrooxireno[20,3’:9,10]cyclodeca[1,2-b]furan-2(3H)-one
4.2.12.1. Method (i). Following general procedure A, a mixture of
parthenolide (100 mg, 0.403 mmol), N-methylaniline (52 mg,
0.48 mmol) and squaric acid (5 mg, 0.04 mmol) was stirred at 50 C
in 1:1 water-methanol (2 mL) for 48 h. The title compound was
obtained as awhite solid in 8% yield (9 mg). Rf¼ 0.67 (hexane/ethyl
acetate, 50%:50%); 1H NMR (400 MHz, CDCl3) d 7.29e7.22 (2H, m),
A.S. Quy, X. Li, L. Male et al. Tetrahedron 76 (2020) 1316316.79e6.70 (3H, m), 5.05 (1H, dd, J 11.8 & 2.3), 4.01 (1H, dd, J 15.4 &
4.9), 3.79 (1H, t, J 9.0), 3.65 (1H, dd, J 15.5 & 6.1), 3.01 (3H, s),
2.74e2.62 (2H, m), 2.41e2.28 (1H, m), 2.19e2.03 (4H, m), 1.96e1.86
(1H, m), 1.79e1.68 (1H, m), 1.64 (3H, s), 1.65e1.53 (1H, m), 1.26 (3H,
s), 1.19 (1H, td, J 13.0 & 5.9); 13C NMR (101 MHz, CDCl3) d 176.0,
149.0, 134.4, 129.5, 125.0, 117.2, 112.5, 82.3, 66.5, 61.6, 52.1, 48.1,
46.4, 40.9, 39.6, 36.6, 30.4, 24.1, 17.2, 16.9; IR (neat, cm1) 1760
(C¼O); HRMS (TOF MS ESþ) m/z: [MþH]þ calc. for C22H30NO3þ
356.2224, found 356.2232;mp 153e156 C; [a]D22¼124.65 (c 1.0,
CH2Cl2).4.2.12.2. Method (ii). Following general procedure B, a mixture of
aminoparthenolide derivative 3a (109 mg, 0.320 mmol), formal-
dehyde (30 mg, 0.96 mmol) and sodium triacetoxyborohydride
(112 mg, 0.528 mmol), was stirred at room temperature in
dichloroethane (10 mL) for 16 h. The title compound was obtained
as a colourless solid in 61% yield (72 mg, 0.20 mmol). 1H NMR, 13C




Following general procedure A, a mixture of parthenolide
(80 mg, 0.32 mmol), 4-fluoro-N-methylaniline (48 mg, 0.38 mmol)
and squaric acid (4 mg, 0.03 mmol) was stirred at 50 C in 1:1
water-methanol (2 mL) for 48 h. The title compound was obtained
as a white solid in 8% yield (9 mg). Rf ¼ 0.64 (hexane/ethyl acetate,
50%:50%); 1H NMR (400 MHz, CDCl3) d 7.02e6.91 (2H, m),
6.75e6.65 (2H, m), 5.07 (1H, dd, J 12.2 & 2.0), 3.92 (1H, dd, J 15.4 &
4.9), 3.80 (1H, t, J 9.0), 3.60 (1H, dd, J 15.4 & 6.0), 2.97 (3H, s), 2.67
(1H, d, J 8.9), 2.63 (1H, ddd, J 11.9, 6.0 & 4.9), 2.44e2.28 (1H, m),
2.19e2.06 (4H, m), 1.89 (1H, dd, J 15.2 & 6.6), 1.76 (1H, t, J 13.0), 1.65
(3H, s), 1.66e1.54 (1H, m), 1.27e1.13 (4H, m); 13C NMR (101 MHz,
CDCl3) d 176.0,145.8,134.3,125.1,115.9,115.7,113.9,113.9, 82.3, 66.5,
61.6, 52.8, 48.1, 46.4, 41.0, 40.1, 36.6, 30.3, 24.1, 17.2, 16.9; 19F-NMR
(377MHz, CDCl3) d128.2; IR (neat, cm1) 1761 (C¼O);HRMS (TOF
MS ASAPþ) m/z: [MþH]þ calc. for C22H29FNO3þ 374.2131, found




Following general procedure A, a mixture of parthenolide
(80 mg, 0.32 mmol), 4-methoxy-N-methylaniline (53 mg,
0.38 mmol) and squaric acid (4 mg, 0.03 mmol) was stirred at 50 C
in 1:1 water-methanol (2 mL) for 48 h. The title compound was
obtained as a white solid in 36% yield (45 mg). Rf ¼ 0.64 (hexane/
ethyl acetate, 50%:50%); 1H NMR (400 MHz, CDCl3) d 6.90e6.81
(2H, m), 6.79e6.71 (2H, m), 5.08 (1H, dd, J 9.8 & 2.1), 3.89 (1H, dd, J
15.2 & 4.8), 3.80 (1H, t, J 9.2), 3.76 (3H, s), 3.52 (1H, dd, J 15.3 & 6.2),
2.93 (3H, s), 2.68 (1H, d, J 8.9), 2.62 (1H, ddd, J 11.9, 6.0 & 4.8),
2.44e2.28 (1H, m), 2.21e2.07 (4H, m), 1.93 (1H, dd, J 14.8 & 6.6),
1.78 (1H, t, J 12.7), 1.64 (3H, s), 1.63e1.51 (1H, m), 1.27 (3H, s),
1.25e1.15 (1H, m); 13C NMR (101 MHz, CDCl3) d 176.2, 152.2, 144.0,
134.5, 125.0, 115.0, 114.9, 82.3, 66.5, 61.6, 55.8, 53.2, 48.1, 46.4, 41.0,
40.4, 36.6, 30.3, 24.1, 17.2, 16.9; IR (neat, cm1) 1766 (C¼O); HRMS
(TOF MS ASAPþ) m/z: [MþH]þ calc. for C23H32NO4þ 386.2331, found
386.2330; mp 146e148 C; [a]D22 ¼ 81.72 (c 2.0, CH2Cl2).8




Following general procedure B, a mixture of aminoparthenolide
derivative 3b (114 mg, 0.319 mmol), formaldehyde (30 mg,
0.96 mmol) and sodium triacetoxyborohydride (112 mg,
0.528 mmol), was stirred at room temperature in dichloroethane
(10 mL) for 16 h. The title compound was obtained as a colourless
solid in 61% yield (72 mg, 0.20 mmol). Rf ¼ 0.49 (hexane/ethyl
acetate, 50%:50%); 1H NMR (400 MHz, CD3OD): d 6.81e6.71 (4H, m,
ArH), 5.14 (1H, dd, J 12.4 & 2.3, CH), 3.97 (1H, t, J 9.1, CH), 3.83 (1H,
dd, J 15.0 & 4.9, CH2), 3.55 (1H, dd, J 15.0 & 6.0, CH2), 2.90 (3H, s,
Me), 2.81 (1H, d, J 9.1, CH, epoxide moiety), 2.80e2.73 (1H, m, CH),
2.51e2.36 (1H, m, CH2), 2.32e2.22 (1H, m, CH2), 2.19e2.03 (3H, m),
1.91 (1H, dd, J 14.6& 6.3, CH2),1.79 (1H, t, J 12.8, CH2),1.71e1.61 (1H,
m, CH2), 1.68 (3H, s, Me), 1.29 (3H, s, Me), 1.22 (1H, td, J 12.7 & 5.9,
CH2); 13C NMR (101 MHz, CD3OD): d 175.2 (C¼O), 148.9 (Cq), 143.6
(Cq), 134.7 (Cq), 124.3 (CH), 115.6 (CH), 82.4 (CH), 66.7 (CH, epoxide
moiety), 61.8 (Cq), 52.9 (CH2), 46.1 (CH), 40.5 (CH2), 39.3 (CH3), 36.2
(CH2), 29.4 (CH2), 23.5 (CH2), 16.0 (CH3), 15.7 (CH3); IR (neat, cm1)
3349 (OH), 1761 (C¼O); HRMS (ESþ) m/z: [MþH]þ calc. for
C22H30NO4þ: 372.2175, found: 372.2172; mp: 192e194 C;
[a]D20 ¼ 6.58 (c 4, CHCl3).
4.2.16. Synthesis of 6 3-((Phenylamino)methyl)dihydrofuran-
2(3H)-one
Following general procedure A, a mixture of tulipane (100 mg,
1.00 mmol), aniline (112 mg, 1.20 mmol) and squaric acid (11 mg,
0.10 mmol), was stirred at 50 C in 1:1 water-methanol (20 mL) for
48 h. The title compound was obtained as a colourless solid in 95%
yield (181mg, 0.948mmol). Rf¼ 0.68 (dichloromethane/methanol,
95%:5%); 1H NMR (400 MHz, CDCl3): d 7.22e7.14 (2H, m, ArH), 6.73
(1H, tt, J 7.3& 1.0, ArH), 6.68e6.62 (2H, m, ArH), 4.40e4.32 (1H, td, J
8.8 & 2.6, CH2), 4.26 (1H, br s, NH), 4.24e4.15 (1H, td, J 9.8 & 6.7,
CH2), 3.52e3.37 (2H, m, CH2), 2.92e2.82 (1H, m, CH), 2.45e2.31
(1H, m, CH2), 2.15e2.05 (1H, m, CH2); 13C NMR (101 MHz, CDCl3):
d 178.5 (C¼O), 147.6 (CeN), 129.4 (CH), 118.1 (CH), 113.2 (CH), 66.8
(CH2), 43.9 (CH2), 39.2 (CH), 26.8 (CH2); IR (neat, cm1) 3345 (OH),
1765 (C¼O); HRMS (ESþ) m/z: [MþNa]þ calc. for C11H13NO2Naþ:
214.0844, found: 214.0837; mp: 60e62 C.
4.2.16.1. Synthesis of 7 (3aS,6R,6aR,9R,9aS,9bS)-9-hydroxy-6-
methoxy-6,9-dimethyl-3-methylenedecahydroazuleno[4,5-b]furan-
2(3H)-one. To a solution of parthenolide (100 mg, 0.403 mmol) in
10 mL of methanol was added squaric acid (5 mg, 0.04 mmol) and
the resulting mixture was stirred at room temperature for three
days. After completion of the reaction, the solvent was removed in
vacuo, the residual was extracted with ethyl acetate (3  25 mL),
the combined organic layers were washed with brine and then
dried over anhydrous magnesium sulphate, filtered, and solvent
removed in vacuo. The product was isolated by flash chromatog-
raphy over silica gel. The title compound was obtained as a col-
ourless solid in 40% yield (45 mg, 0.16 mmol). Rf ¼ 0.46 hexane/
ethyl acetate, 50%:50%); 1H NMR (400 MHz, CDCl3): d 6.22 (1H, d, J
3.5, CH2), 5.51 (1H, d, J 3.3, CH2), 4.21 (1H, dd, J 11.7 & 9.9, CH), 3.19
(3H, s, Me), 2.90e2.72 (2H, m), 2.34 (1H, t, J 11.7, CH), 2.33 (1H, br s,
OH), 2.21e2.12 (1H, m, CH2), 2.01e1.93 (1H, m, CH2), 1.90e1.77 (3H,
m), 1.75e1.66 (1H, m, CH2), 1.60e1.50 (1H, m, CH2), 1.48e1.37 (1H,
m, CH2), 1.39 (3H, s, Me), 1.16 (3H, s, Me); 13C NMR (101 MHz,
CDCl3): d 169.6 (C¼O), 39.0 (Cq), 120.1 (CH2), 82.7 (CH), 80.5 (Cq),
78.1 (Cq), 55.5 (CH), 48.3 (CH3), 46.8 (CH), 46.0 (CH), 39.0 (CH2),
36.0 (CH2), 25.5 (CH2), 24.5 (CH2), 24.3 (CH3), 22.6 (CH3); IR (neat,
cm1) 3470 (OH), 1751 (C¼O); HRMS (ESþ) m/z: [Mþ Na]þ calc. for
C16H24O4Naþ: 303.1572, found: 303.1570; mp: 105e107 C;
A.S. Quy, X. Li, L. Male et al. Tetrahedron 76 (2020) 131631[a]D23 ¼ 2.77 (c ¼ 0.5, CH2Cl2).
4.2.17. Synthesis of 8 (3R,3aS,6R,6aR,9R,9aS,9bS)-3-
((Dimethylamino)methyl)-9-hydroxy-6-methoxy-6,9-
dimethyldecahydroazuleno[4,5-b]furan-2(3H)-one
A mixture of parthenolide analogue 8 (34 mg, 0.12 mmol),
dimethylamine (11 mg, 0.24 mmol) and potassium carbonate
(33 mg, 0.24 mmol), was stirred at room temperature in ethanol
(10mL) for 16 h. The solvent was removed in vacuo and the product
was isolated by flash chromatography over silica gel as a colourless
solid in 89% yield (34 mg, 0.11 mmol). Rf ¼ 0.37 (hexane/ethyl ac-
etate, 50%:50%); 1H NMR (400 MHz, CDCl3): d 4.27 (1H, dd, J 11.6 &
10.2, CH), 3.17 (3H, s, Me), 2.84e2.74 (1H, m, CH), 2.70 (1H, dd, J 12.9
& 5.0, CH2), 2.55 (1H, dd, J 12.9 & 6.6, CH2), 2.46 (1H, br s, OH),
2.40e2.32 (1H, m, CH), 2.32e2.18 (3H, m), 2.24 (6H, s, Me),
2.11e1.99 (1H, m, CH), 1.95e1.77 (3H, m), 1.66 (1H, td, J 13.4 & 3.7,
CH2), 1.60e1.50 (1H, m, CH2), 1.42e1.31 (1H, m, CH2), 1.34 (3H, s,
Me),1.16 (3H, s, Me); 13C NMR (101MHz, CDCl3): d 176.9 (C¼O), 82.9
(CH), 80.2 (Cq), 78.0 (Cq), 58.4 (CH2), 54.9 (CH), 48.5 (CH), 48.1
(CH3), 46.0 (CH3), 45.6 (CH), 44.7 (CH), 39.3 (CH2), 37.8 (CH2), 26.0
(CH2), 25.5 (CH2), 23.7 (CH3), 22.0 (CH3); IR (neat, cm1): 3477
(OH), 1762 (C¼O), HRMS (ESþ) m/z: [M þ H]þ calc. for C18H32NO4þ:
326.2331, found: 326.2323; mp: 138e140 C; [a]D20 ¼ 7.20 (c ¼ 1.5,
CHCl3).
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